LupusTrials.org Archives - Page 3 of 16

Category: LupusTrials.org

Analysis Found Rituximab Biosimilar Showed Effectiveness in Treating Pediatric Lupus Nephritis

Rituximab biosimilar BCD020 showed effectiveness in treating lupus nephritis in a pediatric population according to results of a retrospective study published in the journal Biomedicines. A biosimilar is a medication that is as the name suggests very similar to the drug already approved – in this case rituximab. A retrospective study looks back at information […] Read More

EULAR Presentation Showed Upadacitinib Improved Lupus Disease Activity

May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile. Discovered and […] Read More

Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership

Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs Washington, DC, March 29, 2023 – The Lupus Research Alliance (LRA) today announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. Food and Drug Administration (FDA), […] Read More

Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus […] Read More

New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment […] Read More

Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis

September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults with lupus nephritis, the kidney damage associated with lupus. The drug had also been approved this past January in the U.S. to treat adults with lupus nephritis in combination with a background immunosuppressive medication in […] Read More

Helping Overcome Lupus Effects on Mental Health

Updated March 11, 2022 Neuropsychiatric lupus affects 80-90% of people with lupus. In a video series hosted by the Young Leaders Board of the Lupus Research Alliance, Dr. Meggan Mackay explains How to know if you have neuropsychiatric lupus and offers ways to improve cognitive health. Dr. Mackay also describes a clinical trial she is […] Read More

LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis

NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […] Read More

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] Read More

Study Finds Booster Vaccine Significantly Lowered COVID-19 Infection Risk Among People with Lupus

July 14, 2022 The booster dose of the SARS-CoV-2 vaccine significantly enhanced the degree of protection from COVID-19 infections for people with systemic lupus erythematosus according to a new study reported in The Lancet Rheumatology. People with lupus have been shown to be at high risk for COVID-19 due to the malfunction of their immune […] Read More